Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.44 |
| ▸ | CES1 | P23141 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | F12 | P00748 | 1/20 | 0.36 |
| ▸ | F7 | P08709 | 1/20 | 0.36 |
| ▸ | F3 | P13726 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9194201 | 1.00 | CES2 (0.44) | CES2CES1TSHRALDH1A1DAO | |
| SCHEMBL3846147 | 1.00 | CES2 (0.44) | CES2CES1TSHRALDH1A1DAO | |
| SCHEMBL28126867 | 0.78 | CES2 (0.44) | CES2CES1TSHRALDH1A1DAO | |
| SCHEMBL15656328 | 0.76 | CES2 (0.42) | CES2CES1TSHRALDH1A1DAO | |
| SCHEMBL2458795 | 0.76 | CES2 (0.42) | CES2CES1TSHRALDH1A1DAO | |
| SCHEMBL23728241 | 0.76 | ESR1 (0.48) | TSHRALDH1A1ESR1MAPTLMNA | |
| SCHEMBL23728243 | 0.76 | ESR1 (0.48) | TSHRALDH1A1ESR1MAPTLMNA | |
| SCHEMBL5828005 | 0.76 | CES1 (0.48) | CES2CES1TSHRALDH1A1DAO | |
| SCHEMBL28170573 | 0.76 | CES2 (0.42) | CES2CES1TSHRALDH1A1DAO | |
| SCHEMBL3841892 | 0.74 | CES1 (0.41) | CES2CES1TSHRALDH1A1DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078054-A1 | TIRE FOR VEHICLE WHEELS COMPRISING CROSSLINKED ELASTOMERIC COMPOSITION | Pirelli Tyre S.p.A. (IT) | 2009-07-15 | — | — | EP | claimed |
| WO-2008052571-A1 | TIRE FOR VEHICLE WHEELS COMPRISING CROSSLINKED ELASTOMERIC COMPOSITION | PIRELLI TYRE S.P.A. (IT) | 2008-05-08 | — | — | WO | claimed |
| EP-0047109-B1 | RHODANINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND ALDOSE REDUCTASE INHIBITOR CONTAINING THE RHODANINE DERIVATIVES AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 1985-01-02 | — | — | EP | claimed |
| EP-0047109-A1 | Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 1982-03-10 | — | — | EP | claimed |
| US-11739208-B2 | Block copolymers and uses thereof | Kraton Corporation (US) | 2023-08-29 | — | — | US | disclosed |
| CN-116212122-B | Anticoagulation coating and application and preparation method thereof | 成都德信安创新医疗技术有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-116212122-A | Anticoagulation coating and application and preparation method thereof | 成都德信安创新医疗技术有限公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20230137092-A1 | Composition and Method for the Treatment and Prevention of Cardiac, Pulmonary, Dermal, and Renal Fibrosis | EMERALD HEALTH PHARMACEUTICALS INC. (US) | 2023-05-04 | — | — | US | disclosed |
| EP-4099993-A1 | COMPOSITION AND METHOD FOR THE TREATMENT AND PREVENTION OF CARDIAC, PULMONARY, DERMAL, AND RENAL FIBROSIS | Emerald Health Pharmaceuticals Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220184003-A1 | Formulations of Cannabidiol Derivatives and Their Use as Modulators of Cannabinoid Receptor Type 2 (CB2) | EMERALD HEALTH PHARMACEUTICALS INC (US) | 2022-06-16 | — | — | US | disclosed |
| US-11268952-B2 | Flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof | FIRMENICH INCORPORATED (US) | 2022-03-08 | — | — | US | disclosed |
| EP-3960780-A1 | BLOCK COPOLYMERS AND USES THEREOF | Kraton Polymers Research B.V. (NL) | 2022-03-02 | — | — | EP | disclosed |
| US-5079128-A | Thin film containing a methine dye having at least two dimethylaminophenyl groups and a carbonium ion; laser writing; heat resistance | CANON KABUSHIKI KAISHA (JP) | 1992-01-07 | — | — | US | disclosed |
| US-5079127-A | Methine Dyes | CANON KABUSHIKI KAISHA (JP) | 1992-01-07 | — | — | US | disclosed |
| US-4791126-A | Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredients | ONO PHARMACEUTICAL CO., LTD. (JP) | 1988-12-13 | — | — | US | disclosed |
| EP-0264198-A2 | Optical information recording medium | CANON KABUSHIKI KAISHA (JP) | 1988-04-20 | — | — | EP | disclosed |
| US-4595532-A | N-(substituted-methyl)-azetidin-2-ones | UNIVERSITY OF NOTRE DAME DU LAC (US) | 1986-06-17 | — | — | US | disclosed |
| EP-0116432-A2 | Improvements in or relating to N-(substituted-methyl)-azetidin-2-ones | THE UNIVERSITY OF NOTRE DAME DU LAC (US) | 1984-08-22 | — | — | EP | disclosed |
| US-4464382-A | Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 1984-08-07 | — | — | US | disclosed |
| EP-0047109-A1 | Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 1982-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220184003-A1 | Formulations of Cannabidiol Derivatives and Their Use as Modulators of Cannabinoid Receptor Type 2 (CB2) | CNR2, CNR1, MAG | CES2 1008/4885CES1 1144/4885TSHR 1413/4885 |
| US-20230137092-A1 | Composition and Method for the Treatment and Prevention of Cardiac, Pulmonary, Dermal, and Renal Fibrosis | FABP3, JUP, DSP | CES2 197/4885CES1 216/4885TSHR 4684/4885 |
| US-11268952-B2 | Flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof | TAS2R40, TAS1R2, TAS1R1 | CES2 1724/4885CES1 2306/4885TSHR 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.